Cargando…

The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature

Apatinib is a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, which has been proved to be effective and safe in treating heavily pretreated patients with gastric cancer. The aim of the study was to explore the use of apatinib in treatment of nonsmall cell lun...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Lin, Li, Qing-Jian, You, Kai-Yun, Jiang, Zhi-Min, Yao, He-Rui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902403/
https://www.ncbi.nlm.nih.gov/pubmed/27196461
http://dx.doi.org/10.1097/MD.0000000000003598
_version_ 1782436984329863168
author Ding, Lin
Li, Qing-Jian
You, Kai-Yun
Jiang, Zhi-Min
Yao, He-Rui
author_facet Ding, Lin
Li, Qing-Jian
You, Kai-Yun
Jiang, Zhi-Min
Yao, He-Rui
author_sort Ding, Lin
collection PubMed
description Apatinib is a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, which has been proved to be effective and safe in treating heavily pretreated patients with gastric cancer. The aim of the study was to explore the use of apatinib in treatment of nonsmall cell lung cancer and its side effects. We report 2 patients presented with advanced nonsmall-cell lung cancer, who received apatinib after failure in the first- or third-line chemotherapy. They are treated with apatinib in daily dose of 850 mg, 28 days per cycle. Favorable oncologic outcomes were achieved in the 2 cases after the treatment of apatinib. Patient I's progression-free-survival has increased to 4.6 months after palliative therapy of apatinib, whereas Patient II nearly 6 months. The common side effects of apatinib were hypertension and hand-foot syndrome; however, the toxicity of apatinib was controllable and tolerable. Apatinib may be an option for advanced nonsmall cell lung cancer after failure of chemotherapy or other targeted therapy. But that still warrants further investigation in the prospective study.
format Online
Article
Text
id pubmed-4902403
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-49024032016-06-23 The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature Ding, Lin Li, Qing-Jian You, Kai-Yun Jiang, Zhi-Min Yao, He-Rui Medicine (Baltimore) 5700 Apatinib is a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, which has been proved to be effective and safe in treating heavily pretreated patients with gastric cancer. The aim of the study was to explore the use of apatinib in treatment of nonsmall cell lung cancer and its side effects. We report 2 patients presented with advanced nonsmall-cell lung cancer, who received apatinib after failure in the first- or third-line chemotherapy. They are treated with apatinib in daily dose of 850 mg, 28 days per cycle. Favorable oncologic outcomes were achieved in the 2 cases after the treatment of apatinib. Patient I's progression-free-survival has increased to 4.6 months after palliative therapy of apatinib, whereas Patient II nearly 6 months. The common side effects of apatinib were hypertension and hand-foot syndrome; however, the toxicity of apatinib was controllable and tolerable. Apatinib may be an option for advanced nonsmall cell lung cancer after failure of chemotherapy or other targeted therapy. But that still warrants further investigation in the prospective study. Wolters Kluwer Health 2016-05-20 /pmc/articles/PMC4902403/ /pubmed/27196461 http://dx.doi.org/10.1097/MD.0000000000003598 Text en Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 5700
Ding, Lin
Li, Qing-Jian
You, Kai-Yun
Jiang, Zhi-Min
Yao, He-Rui
The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature
title The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature
title_full The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature
title_fullStr The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature
title_full_unstemmed The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature
title_short The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature
title_sort use of apatinib in treating nonsmall-cell lung cancer: case report and review of literature
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902403/
https://www.ncbi.nlm.nih.gov/pubmed/27196461
http://dx.doi.org/10.1097/MD.0000000000003598
work_keys_str_mv AT dinglin theuseofapatinibintreatingnonsmallcelllungcancercasereportandreviewofliterature
AT liqingjian theuseofapatinibintreatingnonsmallcelllungcancercasereportandreviewofliterature
AT youkaiyun theuseofapatinibintreatingnonsmallcelllungcancercasereportandreviewofliterature
AT jiangzhimin theuseofapatinibintreatingnonsmallcelllungcancercasereportandreviewofliterature
AT yaoherui theuseofapatinibintreatingnonsmallcelllungcancercasereportandreviewofliterature
AT dinglin useofapatinibintreatingnonsmallcelllungcancercasereportandreviewofliterature
AT liqingjian useofapatinibintreatingnonsmallcelllungcancercasereportandreviewofliterature
AT youkaiyun useofapatinibintreatingnonsmallcelllungcancercasereportandreviewofliterature
AT jiangzhimin useofapatinibintreatingnonsmallcelllungcancercasereportandreviewofliterature
AT yaoherui useofapatinibintreatingnonsmallcelllungcancercasereportandreviewofliterature